
    
      The investigators hypothesize that PD-1 blockade combined with CTLA-4 blockade using
      ipilimumab would have a favorable effect on the expansion and activity of human CD8+ T
      cytotoxic lymphocytes (CTLs) specific for tumor-associated antigens (ie, self antigens),
      which would translate into improved anti-cancer therapy.
    
  